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ABSTRACT
Adenosine deaminases that act on dsRNA (ADARs)
are enzymes that target double-stranded regions
of RNA converting adenosines into inosines (A-to-I
editing) thus contributing to genome complexity
and fine regulation of gene expression. It has
been described that a member of the ADAR
family, ADAR1, can target viruses and affect their
replication process. Here we report evidence
showing that ADAR1 stimulates human immuno
deficiency virus type 1 (HIV-1) replication by using
both editing-dependent and editing-independent
mechanisms. We show that over-expression of
ADAR1 in HIV-1 producer cells increases viral pro-
tein accumulation in an editing-independent
manner. Moreover, HIV-1 virions generated in the
presence of over-expressed ADAR1 but not an
editing-inactive ADAR1 mutant are released more
efficiently and display enhanced infectivity, as
demonstrated by challenge assays performed with
T cell lines and primary CD4
+ T lymphocytes. Finally,
we report that ADAR1 associates with HIV-1 RNAs
and edits adenosines in the 5’ untranslated region
(UTR) and the Rev and Tat coding sequence. Overall
these results suggest that HIV-1 has evolved
mechanisms to take advantage of specific RNA edit-
ing activity of the host cell and disclose a stimula-
tory function of ADAR1 in the spread of HIV-1.
INTRODUCTION
One of the best-characterized mechanisms of RNA editing
is the conversion of adenosine to inosine (A-to-I) mediated
by the Adenosine DeAminase enzymes that act on double-
stranded RNA or ADARs. In mammals, three diﬀerent
ADAR enzymes have been identiﬁed: ADAR1, ADAR2
and ADAR3 (1–3). ADAR1 and ADAR2 are expressed in
many diﬀerent tissues (4,5), while ADAR3 is expressed
exclusively in the brain and is inactive on all the RNA
substrates tested in vitro (6,7). The common structural
features shared by ADARs include the N-terminal
double-stranded RNA-binding domains (dsRBDs) and
the catalytic domain at the C-terminus. Human cells
express two diﬀerent ADAR1 isoforms: a constitutive
110-kDa protein (ADAR1 p110) and an interferon
inducible 150-kDa protein (ADAR1 p150) (8). ADAR1
exhibits some features that make this enzyme diﬀerent
from the other two: the presence of two Z-DNA-binding
domains and an extra dsRBD at the amino terminus.
Inosine acts as guanosine during both splicing and
translation events (9,10), therefore A-to-I editing within
pre-mRNA can alter both splicing patterns and amino
acid sequence with important consequences for the ﬁnal
function of the coded protein. Indeed, it has been
shown that RNA editing can profoundly aﬀect the bio-
chemistry of receptors expressed in the brain such as the
glutamate receptor GluR-B, a subunit of the alpha-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
(AMPA), and the serotonin receptor 2C (5-HT2C) (2,3).
Recent evidence demonstrated that most of the A-to-I
substitutions occur within non-coding sequences of pre-
mRNAs enriched in inverted repeated Alu elements,
such as introns and untranslated regions (UTRs)
(11–13). RNA editing of non-coding sequence can alter
the fate of pre-mRNAs by aﬀecting their splicing, locali-
zation, stability or translation (1,3).
ADARs can target viruses, as suggested by numerous
reports showing A-to-I changes identiﬁed in viral genomes
or transcripts that are consistent with editing mediated by
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events described for several negative-stranded RNA
viruses such as measles virus, human parainﬂuenza
virus 3 and respiratory syncytial virus (15), although their
functional consequences are poorly understood. A direct
eﬀect of RNA editing mediated by ADAR1 has been
clearly demonstrated for hepatitis C virus (HCV). The
A-to-I editing of multiple sites within the HCV RNA
replicon impairs viral replication and leads to its clearance
from infected cells (16). There is also evidence of highly
selective editing of viral RNA mediated by ADAR1,
for example the A-to-I editing of the amber/w site in the
antigenomic RNA of hepatitis delta virus (HDV), a
change that is essential for viral replication (17,18).
Despite an increasing attention on the role of A-to-I
RNA editing in the biology of viruses, so far little eﬀort
has been dedicated to testing the involvement of ADARs in
the life cycle of the human immunodeﬁciency virus type 1
(HIV-1). HIV-1 gene expression is tightly regulated at
the level of transcription and maturation of an unspliced
primary transcript (9-kb RNA) in distinct classes of par-
tially and completely spliced RNA molecules (4-kb and
2-kb RNAs). This is accomplished by a coordinated
interaction between viral and cellular factors (19,20). In
addition, HIV-1 RNAs contain several double-stranded
regions, some of them critical for the diﬀerent steps of
the viral life cycle such as the Rev responsive element
(RRE), trans-activation responsive element (TAR) and
dimerization domain (DIS) (19,21,22) that could be possi-
ble ADARs substrates. So far, a report showed A-to-I
editing of TAR sequence in Xenopus laevis (23) and, in a
more recent study, ADAR1 was shown to edit HIV-1 RNA
and enhance the expression of p24 Gag protein (24).
The aim of this study was to further investigate the role
of ADAR1 in the regulation of HIV-1 replication. Here
we report for the ﬁrst time that the RNA editing activity
mediated by ADAR1 stimulates the release and the infec-
tious potential of HIV-1 progeny viruses.
MATERIALS AND METHODS
DNA constructs
The full-length hADAR1 was inserted into the XbaI
restriction site of the pEGFP-C3 (Clontech) with in-
frame EGFP (enhanced green ﬂuorescent protein) at the
N-terminus in order to generate an EGFP-ADAR1 con-
struct. A single point mutation in the catalytic domain of
ADAR1 was introduced directly into the EGFP-ADAR1
construct using a site directed mutagenesis kit (Stratagene)
in order to change the amino acid E955 into A955 within
the catalytic domain (changing the sequence from GAA to
GCA) giving rise to the inactive mutant EGFP-ADAR1
E/A. The PCR reaction was performed following the
manufacturer’s instructions. The EGFP-ADAR1 and the
inactive EGFP-ADAR1 E/A were tested for the editing
activity assay in a cell system (293T) using the miniB13
(encoding a portion of the editing-competent murine
glutamate receptor GluR-B gene) as substrate. All the
DNA constructs were conﬁrmed by sequencing. The
pEGFP-CTNS (cystinosin-expressing construct) was
kindly provided by Dr A. Taranta and Dr F. Emma,
Bambino Gesu ` Children Hospital, Rome, Italy.
Cells and antibodies
293T cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium. Jurkat E6-1, U937 and CEM-GFP cells (25)
were maintained in RPMI 1640 medium. Both media
were supplemented with 10% fetal bovine serum, 2mM
L-glutamine, 100units/ml penicillin–streptomycin. The
medium for CEM-GFP was also supplemented with
100mg/ml G-418. Tissue culture reagents were from
GIBCO-BRL. Western blotting analysis was performed
with the following antibodies: polyclonal rabbit anti-
ADAR1 developed ‘in house’ (26), polyclonal rabbit
anti-p24 (kindly provided by Dr O. T. Fackler,
Heidelberg, Germany), anti-pThr451PKR (Santa Cruz),
anti-PKR (BD Bioscences), and anti-pS51 eIF-2a and
eIF-2a (Cell Signalling), polyclonal goat anti-gp160/
gp120 (HT3, kindly provided by Dr M. Federico,
Istituto Superiore di Sanita ` , Rome), polyclonal sheep
anti-Nef (clone 444, kindly provided by Dr M. Harris,
Leeds, UK), monoclonal anti-tubulin (Sigma) and anti-
GFP (Clontech), and human serum from HIV-1-infected
individual (kindly provided by Dr M. Federico). The PE-
conjugated anti-HIV p24 monoclonal antibody
(KC57-RD1, Coulter Immunology) was used for ﬂow
cytometry.
HIV-1 expression and detection
293T cells were transfected with the indicated amounts of
pNL4-3 proviral plasmid (NIH reagent program) alone or
with pEGFP-derived vectors by using the standard
calcium-phosphate method. Forty-eight hours post-
transfection, cells were analyzed by western blotting and
culture supernatants were collected, clariﬁed by low-speed
centrifugation, and stored in aliquots at –808C. Viral
stocks were titrated by anti-p24 ELISA (Immunogenetics
NV) according to the manufacturer’s instructions.
HIV-1 infection
To evaluate viral infectivity, CEM-GFP indicator cells
were infected in triplicate for 4h at 378C with 400ng of
p24/5 10
4 cells of virus and 2mg/ml of polybrene. This
virus dose resulted in a percentage of infected cells that
matched the linear range of infectivity, as determined in
pilot experiments with serial dilutions of viral prepara-
tions. After viral exposure, cells were washed twice and
resuspended at 5 10
5 cells/ml. After 40h, cells were col-
lected and the number of GFP+ cells was determined by
ﬂow cytometric analysis. For HIV-1 infection of primary
human CD4
+ T lymphocytes, puriﬁed cells were derived
from healthy donors as described (27). To evaluate the
eﬃciency of single-cycle infection, CD4
+ T cells were
infected by incubation for 4h at 378C with 100ng of
p24/10
6 cells of virus. Then, cells were washed twice, resus-
pended at 1.5 10
6/ml in complete RPMI medium supple-
mented with 100IU/ml of human rIL-2, and stimulated by
the addition of PHA (SIGMA) at a ﬁnal concentration
of 3mg/ml and irradiated allogeneic PBMCs at a 1:1
ratio. Finally, infected CD4
+ T cells were harvested
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infectivity was calculated as percentage of p24+ cells
with the control virus produced by EGFP-expressing
293T set at a 100%.
Flow cytometry
For detection of intracellular p24 in HIV-1-infected
CD4
+ T cells, 5 10
5 infected or uninfected cells were
ﬁxed and permeabilized with reagents from BD
Biosciences and incubated with the PE-conjugated anti-
HIV p24 mAb. Finally, cells were washed, resuspended
in 1% paraformaldehyde and analyzed by ﬂow cytometry
on a FACSCalibur with CellQuest software (Becton
Dickinson).
Western blotting analysis
Cells were lysed in buﬀer containing 1% Triton X-100 as
described elsewhere (28). Equal amounts of total cellular
lysates (40mg) were separated by 10% SDS–PAGE, trans-
ferred on nitrocellulose and analyzed by immunoblotting
with the appropriate antibodies and the ECL system
(Amersham Pharmacia Biotech) as previously described
(28). The proteins’ speciﬁc signals were quantiﬁed by
densitometric analysis.
Determination of HIV-1 RNA editing sites
Total RNA was isolated with TRIzol reagent (Invitrogen)
from transfected 293T cells according to the manufac-
turer’s instructions. The cDNA pools generated by
SuperScript III reverse transcriptase (Invitrogen) using
1mg of total RNA and random hexamer primers were
ampliﬁed by PCR using Expand High Fidelity PCR
System (Roche) and speciﬁc primers for the analysis of
diﬀerent HIV-1 RNA regions. TAR50 (50-GGGTCTCTC
TGGTTAGACCAG-30) and TAR2R (50-CTGCTAGAG
ATTTTCCACACTG-30) were used to amplify a fragment
of 181bp containing a region of the 50 UTR shared by all
the viral transcripts. Rev-forward (50-ATGGCAGGAAG
AAGCGGAGAC-30) and Rev-reverse (50-CTATTCTTT
AGTTCCTGACTCC-30) were used to amplify a frag-
ment of 351bp containing the Rev mRNA coding
sequence. Tat-forward (50-ATGGAGCCAGTAGATCC
TAGAC-30) and Tat-reverse (50-CTAATCGAATGGAT
CTGTCTCTG-30) were used to amplify a fragment of
306bp containing the Tat mRNA coding sequence. For
the sequence analysis of the 50 UTRs harbored in the three
diﬀerent HIV-1 RNA species (2kb, 4kb and 9kb), the
cDNA pools were ﬁrst subjected to PCR reaction using
the TAR50 forward primer and three diﬀerent reverse pri-
mers as previously described (29) to amplify speciﬁc frag-
ments of the three viral RNA species. The resulting PCR
products were subjected to a second PCR reaction with
TAR50 and TAR2R primers to amplify a fragment of
181bp containing part of the 50 UTR. The resulting
RT–PCR products were analyzed by direct sequencing.
The extent of editing at each site was determined
by using the electropherograms from the sequencing
reactions to estimate the relative amounts of A and G
(30). Total RNA isolated from three independent
co-transfection experiments was used for RT–PCR and
sequencing analysis.
Immunoprecipitation experiments and RT–PCR analysis
Transfected 293T cells were homogenized and immuno-
precipitated with anti-ADAR1 antibody as previously
described (26). The resulting beads were washed ﬁve
times with PBS 1  and one-fourth of them were resus-
pended in SDS sample buﬀer for western blotting analysis.
The remaining beads were ﬁrst incubated with lysis buﬀer
in the presence of 60 units RQ1 DNase (RNase free) for
30min at 378C, washed three times with PBS 1  and then
incubated with lysis buﬀer with 5mM EDTA, 0.5% SDS
and 50mg proteinase K (Promega) for 20min at 508C.
Co-precipitated RNA was isolated by phenol and chloro-
form extraction method followed by ethanol precipitation.
Each RNA sample was DNase treated (Promega, RQ1
DNase) and used for RT–PCR experiments using
random hexamer and M-MLV reverse transcriptase
(Invitrogen) according to the manufacturer’s instructions.
The resulting cDNA was ampliﬁed by PCR using the
TAR50 and TAR2R primers (see above) to detect the
TAR hairpin located at the extreme 50 termini of all
HIV transcripts, the C primer (50-CTTCTAAGCATCTT
AAATTTGC-30) and D primer (50-TTTAGCCTATGAG
ATCTGGATGTGC-30) to detect the miniB13 trans-
cript, and the GAPDH50 (50-ACCACAGTCCATGCCA
TCAC-30) and the GAPDH30 (50-TCCACCACCCTGTT
GCTGTA-30) primers to detect GAPDH mRNA. To
determine the HIV-1 RNA species that are speciﬁcally
co-immunoprecipitated with anti-ADAR1 antibody,
three diﬀerent reverse primers were used as previously
described (29) while TAR50 was used as the forward
primer.
RESULTS
T lymphocytes express ADAR1
To establish a model system for studying the interaction
between ADAR1 and HIV-1, we ﬁrst evaluated ADAR1
expression in viral cell targets (primary CD4
+ T lympho-
cytes, Jurkat leukaemic T cell line, and U937 monocyte
lymphoma cell line) as well as in 293T, an embryonic
kidney cell line that is widely used for in vitro HIV-1 pro-
duction. Western blotting analysis of total cell lysates
showed that ADAR1 is expressed in both CD4
+ T
and Jurkat cells (Figure 1), in agreement with previous
Figure 1. ADAR1 expression in HIV-1 target cells. An amount of 40mg
of total cell lysates from freshly puriﬁed CD4
+ T lymphocytes, Jurkat,
U937 and 293T cells were analyzed by western blotting analysis with
anti-ADAR1 rabbit serum. Both the long (p150) and short (p110)
isoforms of ADAR1 are indicated.
5850 Nucleic Acids Research, 2009, Vol. 37,No. 17studies describing A-to-I RNA editing in human T lym-
phocytes (31–33). 293T cells express comparable levels
of ADAR1 (Figure 1), although these cells display very
low/undetectable editing activity on endogenous or
plasmid-derived RNA substrates of ADAR enzymes
(26,34,35). In contrast, U937 cells express only barely
detectable levels of ADAR1 p110. Thus, U937 cell line
was excluded from further analysis and this study focused
on a T-tropic HIV-1 strain, NL4-3.
HIV-1 protein expression is regulated by ADAR1
independently of its editing activity
Recent evidence suggested that ADAR1 enhances the
expression of the p24 Gag protein of HIV-1 (24). To
further investigate this phenomenon, 293T cells were
co-transfected with the NL4-3 proviral DNA and a
vector expressing EGFP-ADAR1 or EGFP-ADAR1
E/A mutant that lacks editing activity. For controls, a
vector expressing an unrelated EGFP-tagged protein
(cystinosin or CTNS) or, alternatively, pEGFP vector
alone was used. Comparable transfection eﬃciency was
conﬁrmed by determining the percentage of EGFP-
positive cells by ﬂow cytometric analysis (data not
shown). Forty-eight hours post-transfection, total cell
extracts were prepared and analyzed by western blotting
with antibodies speciﬁc for EGFP, HIV-1 Nef protein,
tubulin, and with a total serum of an HIV-infected
patient. Strikingly, the entire set of viral proteins detected
with the anti-HIV-1 human serum was strongly enhanced
over-expressing ADAR1 if compared to the control
EGFP-CTNS- or EGFP-expressing cells (Figure 2A and
B). In addition, a similar increase in HIV-1 proteins was
observed upon over-expression of the ADAR1 E/A
mutant (Figure 2A). The levels of three HIV-1 proteins,
gp120 envelope protein, p24 Gag capsid antigen, and the
regulatory Nef protein, were analyzed with speciﬁc anti-
bodies (Figure 2A and data not shown) and calculated in
four independent experiments by considering as 100% the
relative expression in control cells (Figure 2C). Results
showed that over-expression of ADAR1 increases the
levels of gp120, p24 and Nef by about 3-, 7- and 2-fold,
respectively. Importantly, since a similar eﬀect was
observed also with the ADAR1 E/A mutant, the function
of ADAR1 on HIV protein expression is editing-indepen-
dent. Indeed, ADAR1 was previously shown to stimulate
the replication of vesicular stomatitis virus (VSV) in an
editing-independent manner through the inhibition of
the RNA-activated protein kinase PKR that would other-
wise shut down protein synthesis by phosphorylating the
a subunit of eukaryotic initiation factor 2, eIF-2a (36).
Therefore, we tested the status of PKR and its substrate
eIF-2a in our experimental cell system by performing
western blotting analysis with speciﬁc antibodies against
total PKR and eIF-2a proteins and against their phos-
phorylated forms (pThr451PKR and pS51 eIF-2a). As
shown in Figure 2D, upon expression of EGFP-ADAR1
with or without HIV-1 expression, the low basal level
of phosphorylated PKR became undetectable and the
phosphorylated eIF-2a was reduced by about 30%.
Down-regulation of pThr451PKR and pS51eIF-2a was
also observed in cells expressing EGFP-ADAR1 E/A.
These data suggest that the editing-independent capacity
of ADAR1 to stimulate HIV-1 protein expression may be
contributed by the enzyme’s inhibitory activity on PKR
function.
ADAR1 increases the release of progeny virions
To further investigate the role of ADAR1 in the biology of
HIV-1, we analyzed the release of viral particles produced
by cells over-expressing either EGFP-ADAR1 or EGFP-
ADAR1 E/A mutant. 293T cells were transfected as
described above and 48h later p24 expression was mea-
sured in both cellular lysates and in cell culture media by
means of western blotting analysis and ELISA, respec-
tively (Figure 3A and B show a representative experi-
ment). The relative HIV-1 release was calculated in four
independent experiments by setting at a 100% the release
of viral particles in the absence of ADAR1 over-expres-
sion (Figure 3C). We found that both EGFP-ADAR1 and
EGFP-ADAR1 E/A over-expressed in producer cells
increased the intracellular accumulation and the concen-
tration in the cell supernatant of p24 (Figure 3A and B).
However, over-expressed EGFP-ADAR1 but not EGFP-
ADAR1 E/A resulted in a 2-fold higher release of viral
particles (Figure 3C). These data show that the productive
assembling and/or release of HIV-1 progeny virions can be
stimulated by ADAR1 through its editing activity.
ADAR1 stimulates HIV-1 infectivity
Next, the impact of ADAR1 in the infectivity of viral
particles was analyzed. The viruses produced by cells
expressing EGFP, EGFP-ADAR1 or EGFP-ADAR1
E/A were quantiﬁed measuring by ELISA the p24 protein
concentration in the culture supernatant and used for
single-round infection of CEM-GFP indicator cells
(400ng of p24/5 10
4cells). Figure 4A and B show that
the virus produced by EGFP-ADAR1+ cells displayed an
infectious capacity about 2.5-fold higher than that of virus
released by control EGFP+ cells. A smaller increase in
viral infectivity was also observed when EGFP-ADAR1
E/A was expressed in producer cells, although it did not
diﬀer signiﬁcantly from control virus. Moreover, the
stimulatory eﬀect of EGFP-ADAR1 on viral infectivity
was dose-dependent (Figure 4C) and maintained when dif-
ferent cell targets were used such as Jurkat cells (data not
shown) and, more importantly, primary CD4
+ T lympho-
cytes (Figure 4D and E). Taken together, these results
indicated that ADAR1 increased the infectious potential
of HIV-1 through an editing-dependent mechanism.
HIV-1 RNAs associate with ADAR1
Given that ADARs exert their editing activity upon bind-
ing to dsRNA, the physical interaction between ADAR1
and HIV-1 RNAs was tested by co-immunoprecipitation
experiments. 293T cells were transiently co-transfected
with miniB13 plasmid (encoding a natural substrate of
ADAR1), and pEGFP-ADAR1 expression vector in
the presence or absence of NL4-3 proviral DNA. 48h
post-transfection total cell extracts were prepared and
immunoprecipitated with either anti-ADAR1 antibody
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ﬁrmed that ADAR1 was speciﬁcally immunoprecipitated
with anti-ADAR1 antibody in the presence and absence of
HIV-1 (Figure 5A and data not shown). An RT–PCR
analysis performed on RNA extracted from the immuno-
precipitates demonstrated that ADAR1 speciﬁcally binds
both HIV RNAs and miniB13 transcript but not GAPDH
mRNA (Figure 5B). Moreover, by performing RT–PCR
analysis speciﬁc for the three diﬀerent HIV-1 RNA classes
(9-kb primary transcript, 4-kb singly spliced and 2-kb
completely spliced RNAs), we demonstrated that all
viral transcripts are speciﬁcally co-immunoprecipitated
with ADAR1 (Figure 5C).
ADAR1 edits HIV-1 RNAs
Finally, we investigated whether ADAR1 binding to
HIV-1 transcripts resulted in editing of viral sequences.
Co-transfection experiments with NL4-3 proviral DNA
and either pEGFP-ADAR1 or pEGFP-ADAR1 E/A
were carried out in 293T cells. Total RNA isolated
from the transfected cells was subjected to reverse tran-
scription generating cDNA pools that were ampliﬁed by
PCR using speciﬁc primers for the analysis of diﬀerent
HIV-1 regions and then sequenced. Inosine is read as gua-
nosine during reverse transcription; therefore the A-to-I
changes in the RNA appear as A-to-G changes in the
Figure 2. ADAR1 enhances HIV-1 protein expression. (A) Total cell lysates (40mg) prepared from 293T cells transfected with 5mg of pNL4-3
proviral plasmid together with 3mg of pEGFP-CTNS, pEGFP-ADAR1 or pEGFP-ADAR1 E/A (lanes 1, 2 and 3) or mock transfected (lane 4) were
analyzed by western blotting with antibody speciﬁc for GFP, HIV total proteins, Nef and tubulin. (B) Western blotting was performed as described
in panel A with lysates of 293T cells mock transfected (lane 1), transfected with 5mg of pNL4-3 together with 3mg of pEGFP or pEGFP-ADAR1
(lanes 2 and 3). (C) The average levels of gp120, p24 and Nef HIV-1 proteins were calculated by densitometric analysis of the corresponding bands
normalized by tubulin (data not shown) in four independent experiments like the one shown in panel A and by setting at a 100% the value obtained
in EGFP-CTNS+ control cells. As calculated by paired t-test, signiﬁcant diﬀerences between control and other samples are indicated (
 P<0.05).
The error bars represent standard deviations (SD). (D) The expression of total or phosphorylated PKR and eIF-2a was evaluated by western blotting
analysis of lysates from 293T mock transfected (lane 1), co-transfected with pNL4-3 and pEGFP-CTNS, pEGFP-ADAR1 or pEGFP-ADAR1 E/A
(lanes 2, 3 and 4, respectively) or transfected with pEGFP-ADAR1 alone (lane 5).
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ing events in both non-coding and coding RNA, a region
of the 50 UTR shared by all HIV RNAs (rich in double-
stranded hairpins that are crucial for viral replication) and
Rev and Tat mRNA coding sequences were analyzed. This
analysis revealed the presence of editing events in viral
RNAs (Figures 6 and 7 and Supplementary Figures 1
and 2) isolated from 293T cells over-expressing EGFP-
ADAR1 but not EGFP-ADAR1 E/A mutant or EGFP
alone (Figure 6 and Supplementary Figure 1). In the 50
UTR, ﬁve editing events were identiﬁed (Figure 6A and
B), four of which (edited sites 520, 521, 551 and 552)
occurred at sites located within the poly(A) hairpin that
encompasses the AAUAAA polyadenylation signal
(Figure 6C). The poly(A) hairpin is a functional element
of the repeat (R) region of the 50 UTR sequence and
is reiterated at the extreme 30 end of viral RNA where it
is required for 30 end formation. Notably, the analysis of
the processed poly(A) hairpin located at 30 terminus of the
polyadenylated viral transcripts did not reveal any A-to-I
modiﬁcations (data not shown).
Since we analyzed a region of the 50 UTR shared by all
HIV-1 RNAs, the A-to-I changes identiﬁed represent the
sum of all the editing events occurred in the various viral
transcripts. Therefore, we further extended our analysis
to distinguish the 50 UTR harbored in each HIV-1 RNA
class (9kb, 4kb or 2kb) and determined that editing
occurred in all viral transcripts, albeit with diﬀerent
eﬃciencies, with the highest level of editing found in the
completely spliced 2-kb transcripts and the lowest in the
9-kb primary transcript (Supplementary Figure 2).
Direct sequence analysis of the RT–PCR fragments
corresponding to viral coding regions allowed identiﬁca-
tion of six major editing events in Rev and one in
Tat sequence. While ﬁve out of six editing events occurring
within the Rev coding sequence (Figure 7 and Supplemen-
tary Figure 1A) lead to codon changes that altered the
protein primary sequence, the single editing event detected
in the Tat sequence does not (Figure 7 and Supplementary
Figure 1B). Since Tat and Rev exons partially overlap
within the HIV-1 genome, their corresponding transcripts
share some coding sequences. Interestingly, a common
adenosine (A6036) is edited by ADAR1 in both viral
transcripts although with diﬀerent eﬃciencies (32% in
Tat mRNA, Supplementary Figure 1B and 67% Rev
mRNA, Supplementary Figure 1A), suggesting that this
residue corresponds to a hot spot for ADAR1.
Overall these results prove that HIV-1 RNAs can be
edited by ADAR1. Moreover, the identiﬁcation of
ADAR1-speciﬁc A-to-I changes in the viral sequences
supports and correlates with the evidence of an ADAR1
editing-dependent stimulatory activity on virus release
and infectivity.
DISCUSSION
Here we provided evidence of a possible role for ADAR1
in the regulation of some critical steps of the HIV-1 life
cycle. We showed that over-expressed ADAR1 strongly
increases the overall accumulation of HIV-1 proteins in
producer cells independently of its editing activity
(Figure 2). This mechanism may rely on the previously
described capacity of ADAR1 to bind and inhibit the
PKR kinase that, once phosphorylated/activated, can sup-
press protein synthesis by phosphorylating eIF-2a (36).
Indeed, in cells over-expressing wt or inactive ADAR1
we observed reduced levels of phosphorylated PKR
and eIF-2a that could account for enhanced synthesis of
HIV-1 proteins (Figure 2C). However, further studies are
needed to test whether ADAR1 can stimulate HIV-1
expression by additional editing-independent mechanisms,
for instance through protein-protein interactions with cel-
lular factors that regulate RNA transcription and/or
translation, as previously reported with nuclear
factor 90 (NF90) (37). Moreover, results here presented
demonstrated that HIV-1 virions produced in ADAR1
over-expressing cells are released more eﬃciently and,
importantly, displayed a higher infectious potential
(Figures 3 and 4). These eﬀects of ADAR1 on HIV-1
viral particles apparently depend on its editing activity.
It is possible that ADAR1-mediated editing in mRNAs
coding for encapsidated viral proteins and/or cellular
co-factors that participate in virion assembly and release
Figure 3. The release of HIV-1 virions is stimulated by ADAR1. 293T
cells were co-transfected as described in Figure 1A with pNL4-3 and
the indicated pEGFP-based vectors. (A) After 48h, cell lysates were
prepared and analyzed by western blotting with antibodies speciﬁc
for p24 and tubulin to evaluate the steady-state expression of intracel-
lular p24. (B) In addition, virion production from transfected 293T was
measured by p24 capture ELISA of culture supernatant. (C) The eﬃ-
ciency of viral release was calculated by dividing the total amount of
p24 in the culture supernatant by the amount of intracellular p24 nor-
malized by tubulin (densitometric units) and by setting at a 100% the
release of viral particles in the presence of EGFP-CTNS. Results shown
are the mean   SD of four independent experiments including the one
shown in panels A–B (
 P<0.05).
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viral particles.
Indeed, in this study we demonstrated that ADAR1
binds to the three diﬀerent classes of HIV-1 RNA
(Figure 5) and identiﬁed editing events in both coding
and non-coding regions of viral transcripts (Figures 6
and 7 and Supplementary Figure 1).
The sequence analysis of viral RNAs isolated from
ADAR1 wt over-expressing cells showed speciﬁc A-to-I
changes in a region of the 50 UTR shared by all viral
transcripts as well as in the Rev and Tat mRNA coding
sequences, providing the proof that ADAR1 can target
and modify HIV-1 RNAs.
The adenosines that are targeted by ADAR1 in the
50 UTR of the viral transcripts are mostly clustered in
the poly(A) hairpin (Figure 5C), and their editing can
alter the thermodynamic stability of the dsRNA structure
(data not shown). The poly(A) hairpin motif in the
50 UTR is highly conserved and essential for viral replica-
tion (38,39). The sequence of the 50 UTR downstream of
the common region analyzed (the ﬁrst 181nt) diﬀers in
various HIV-1 RNAs due to alternative ligation with
distal exons (40). Interestingly, the analysis of the
common region of 50 UTR in the three HIV-1 RNA
classes showed that the 2-kb transcripts are more eﬃ-
ciently edited by ADAR1 than the other species
Figure 4. ADAR1 increases the infectivity of progeny virions. EGFP+, EGFP-ADAR1+ and EGFP-ADAR1 E/A+ viruses were produced by
293T cells transfected with pNL4-3 (15mg) together with pEGFP (8mg), pEGFP-ADAR1 (8mg and 1, 4 and 8mg in panel C), or pEGFP-ADAR1
E/A (8mg), respectively. (A) Equal amounts of virus were used for single-round infections of CEM-GFP target cells as described under ‘Materials and
Methods’ section. Forty-eight hours post-infection, the relative percentage of GFP+ cells was analyzed by ﬂow cytometry. The unshaded histogram
show uninfected cells. Results shown in (B) and (C) are the mean SD determination from at least three independent experiments (
  P<0.01).
(D) Freshly isolated CD4
+ T lymphocytes have been infected, activated and analyzed after 3 days by ﬂow cytometry to evaluate the percentage of
p24+ cells as soon as they appeared. The unshaded histogram show uninfected cells. (E) The eﬃciency of viral infectivity was calculated in three
independent experiments as percentage of p24+ cells with the control virus produced by pEGFP-transfected cells (EGFP+) set at a 100%.
5854 Nucleic Acids Research, 2009, Vol. 37,No. 17(Supplementary Figure 2). This result could be explained
by the diﬀerent ADAR1-binding aﬃnity for the diverse 50
UTR of viral transcripts. In addition, a common adeno-
sine residue (A6036) is edited with higher frequency in the
Rev RNA (67%) if compared to the Tat RNA (32%),
suggesting a higher binding aﬃnity of ADAR1 for the
Rev-speciﬁc 2-kb transcript. An alternative explanation
that does not exclude the former is that editing of the
A6036 residue in the 9-kb primary transcript may lead to
its preferential processing into the Rev RNA. Of note,
A6036 resides in a regulatory region that contributes to
the splicing site selection necessary for the generation of
the Rev RNA as well as other viral transcripts (41).
While the only editing identiﬁed in the Tat sequence
causes a codon change that doesn’t alter primary protein
sequence (Figure 7 and Supplementary Figure 1), ﬁve out
of six editing events found in the Rev coding sequence lead
to amino acid changes in motifs that are crucial for the
regulative function of Rev (Figure 7 and Supplementary
Figure 1) (42), such as the oligomerization motif, Nuclear
localization signal and RNA-binding (RRE) motif, and
Nuclear export signal. How the editing events identiﬁed
mediate the eﬀects we have observed on HIV-1 virions
remains to be investigated. We believe that an extensive
sequencing analysis to gain a complete mapping of the
A-to-I changes occurring in HIV-1 RNA sequence will
help to identify the speciﬁc adenosines critical for the
biological eﬀects we have observed.
Preliminary analysis of the HIV-1 RNA isolated from
CD4
+ T infected in vitro indicate that A-to-G is the most
frequent change occurring in the Rev coding sequence
(data not shown). It is unlikely that the observed A-to-G
changes resulted from errors of the HIV-1 RT enzyme
since this would imply an insertion of dCTP opposite
Figure 5. ADAR1 associates with HIV-1 RNAs. 293T cells were transiently co-transfected with miniB13 plasmid (2mg) and pEGFP-ADAR1 (8mg)
in the presence or absence of NL4-3 proviral DNA (15mg). Forty-eight hours post-transfection total cell extracts were prepared and immunopre-
cipitated with anti-ADAR1 antibody or with control rabbit IgGs. (A) Western blotting analysis of an aliquot of the immunoprecipitated proteins and
total cell extract probed with anti-ADAR1 antibody. (B) RNA isolated from the immunoprecipitates was retrotranscribed and ampliﬁed by PCR
using speciﬁc primers to detect the TAR sequence harbored at the extreme 50 end of all HIV-1 transcripts, the miniB13 transcript and the endogenous
GAPDH mRNA. As a positive control, an RT–PCR experiment was performed with total RNA isolated from 293T co-transfected with miniB13
plasmid along with pEGFP-ADAR1, and NL4-3 proviral DNA (Cell ext.). Exclusion of RT from the RT–PCR reaction served as a speciﬁc negative
control. (C) An RT–PCR analysis was carried using speciﬁc primers designed to distinguish the diﬀerent HIV-1 RNA species (unspliced 9-kb RNA,
spliced 4-kb and 2-kb RNAs) associated with ADAR1.
Nucleic Acids Research, 2009,Vol.37, No. 17 5855Figure 6. A-to-I RNA editing at speciﬁc sites in the 50 UTR of HIV-1 RNAs. The 50 UTR sequence of HIV-1 was analyzed by direct sequencing of
RT–PCR products generated using as substrate the total RNA isolated from 293T cells co-transfected with NL4-3 proviral DNA (15mg) together
with either pEGFP (8mg) or pEGFP-ADAR1 (8mg) or pEGFP-ADAR1 E/A (8mg) plasmids. (A) Edited adenosines in the 50 UTR sequence analyzed
are shown in bold and underlined and their nucleotide position in the HIV-1 genome is indicated (NL4-3 numbering). (B) Representative DNA
sequencing chromatograms of the RT–PCR products. Edited adenosines appear as mixture of A and G, and the estimated percentage of editing
eﬃciency is indicated (30). Results shown are representative of three independent co-transfection experiments. (C) Schematic representation of
the poly(A) hairpin (generated by using mfold server: http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi) harbored in the 50 UTR of HIV-1 RNA.
Red arrows show adenosines that undergo ADAR1 editing and their relative nucleotide position in the HIV-1 genome.
Tat sequence
Rev sequence
5′-//.. (6019)ACT CAT CAA GCT TCT CTA TCA AAG CA(6044) ..//-3′′
L/L
(6036)
5′-//.. (6019)A CTC ATC AAG CTT CTC TAT CAA AGC A(6044) ..//-3′
Y/C
(6036)




5′-//.. (8503)GTG CCT CTT CAG CTA CCA CCG CTT GAG  (8529) ..//-3′
(8513) (8517)
Q/R L/L
Figure 7. A-to-I RNA editing at speciﬁc sites in the Rev and Tat coding sequence. The Rev and Tat coding sequence were analyzed by direct
sequencing of RT–PCR products generated using as substrate the total RNA isolated as described in Figure 6. Three independent co-transfection
experiments with relative RT–PCR analysis were carried out. The edited adenosines found in the Rev and Tat coding sequence are numbered
(relative to NL4-3) and shown in bold. The codons encompassing modiﬁed adenosines are underlined and the corresponding amino acids
(before/after editing) are indicated.
5856 Nucleic Acids Research, 2009, Vol. 37,No. 17to A in viral RNA, an event that occurs very rarely com-
pared to a normal Watson–Crick base pair formation
(A+dTTP) (43). The most plausible explanation for
these changes is that the Rev RNA is edited by cellular
ADAR enzymes during HIV-1 replication in CD4
+ T
cells. Interestingly, adenosines that are modiﬁed in
CD4
+ T cells do not coincide with those targeted by
ADAR1 in 293T cells although some are located in close
proximity. Several factors may inﬂuence the speciﬁcity of
ADAR1 including cell-speciﬁc proteins that modulate
ADAR1 activity and/or the local structure of viral RNA
and the ratio between the enzyme and its target RNA
substrate. Indeed, Phuphuakrat and colleagues (24)
showed that in the monkey COS7 cell line HIV-1 RNA
is edited by ADAR1 at sites diﬀerent from those found in
the present study. In addition, both the frequency and
speciﬁcity of editing events in the HIV-1 RNA varied
upon ADAR1 over-expression in COS7 cells (24).
Variation of RNA editing speciﬁcity seems to be a feature
shared by other viruses (44,45). Of note, during the course
of HIV-1 infection the levels and/or the function of
ADAR1 may be modulated, as suggested by the fact
that in T lymphocytes proinﬂammatory stimuli may
increase both the expression and the activity of the
ADAR1 enzyme (32). Future studies are needed to under-
stand the regulation of viral RNA editing as well as the
impact of ADAR1 in the viral life cycle.
Our study conﬁrms and extends a recent report showing
that ADAR1 over-expression in HIV-1 producer cells
increases extra-cellular levels of the p24 protein in an
editing-dependent manner (24). Here, we disclose a novel
function of ADAR1 in the stimulation of virion release
and infectivity (Figure 3 and 4). On the other hand,
Phuphuakrat and colleagues (24) found that the virus pro-
duced from ADAR1-overexpressing COS7 cells exhibits
normal infectivity if tested on GHOST-CXCR4 cells.
Diﬀerences in the experimental systems employed may
possibly account for this discrepancy. In particular,
we used 293T cells to produce the virus and natural
HIV-1T cell targets (CEM-GFP and Jurkat cell lines as
well as primary CD4
+ T lymphocytes) to evaluate viral
infectivity. Diﬀerent cell systems employed may also
account for divergent editing events found in the non-
coding TAR region of HIV-1 transcripts that was ana-
lyzed in both studies.
It is well known that editing enzymes that belong to the
APOBEC family of cytidine deaminases can edit HIV-1
DNA (46). In particular, human APOBEC3G mediates
extensive cytidine deamination in the viral-minus strand
DNA and induces multiple G-to-A changes in viral plus
strand during reverse transcription. These hypermutations
lead to incomplete reverse transcription or production of
non-functional viral proteins (46). It’s intriguing that edit-
ing of HIV-1 at the DNA and RNA level mediated by two
diﬀerent host enzymes APOBEC3G and ADAR1 could
exert opposing eﬀects on viral replication. The interaction
of APOBEC3G and ADAR1 with HIV-1 and their
possible coordinated interplay may shed light on a novel
regulatory network that could take place in the infected
host cells.
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